by Wim Mees | Oct 25, 2023 | Press release
myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics. myNEO Therapeutics to focus on building proprietary neoantigen discovery product pipeline based on a novel class of shared therapeutic cancer...by Wim Mees | Sep 21, 2023 | Team events
Congrats Lore Van Oudenhove, the winner of the first myNEO soccer cup! This summer we organised a table football cup where everyone of the team competed against each other. The third place playoff was won by Bruno Fant against Manon Montyne. Lore won the final after a...by Wim Mees | Jun 11, 2023 | Team events
Coming together is a beginning, staying together is progress, and working together is success! Just before summer we had a blast during the myNEO teambuilding where we had so much fun with different collaboration and competition games. While our team continues to...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).